Dukes on Water is officially closing down on Friday night, May 15.Co-owner Andrea Shafton says the closure is not about safety concerns and has been in the works. “Our family has ...
Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration ...
GlobalData on MSN
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
Vietnam Investment Review on MSN
Ribo partners with Insilico Medicine on AI-driven RNA drugs
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ...
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with ...
MarketBeat on MSN
CRISPR Therapeutics enters 'second phase' as CASGEVY momentum builds, pipeline data looms
3 Biotech Stocks That Could Benefit from the Patent Cliff CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam ...
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...
It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...
Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico ...
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a ...
Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results